Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reijo Laaksonen

Showing results (1-10 of 152) with videos related to

Pageof 16
Sort By:
Cardiovascular Drugs and Therapy|February 21, 2016
Identifying new Risk Markers and Potential Targets for Coronary Artery Disease: The Value of the Lipidome and MetabolomeReijo Laaksonen
Drug Discovery Today|September 24, 2013
Lipidomics in drug discoveryTerhi Vihervaara, Matti Suoniemi, Reijo Laaksonen
Angiology|July 18, 2008
Lipidomics-based safety biomarkers for lipid-lowering treatmentsReijo Laaksonen, Minna T Jänis, Matej Oresic
Expert Opinion on Drug Metabolism & Toxicology|July 10, 2008
Metabolomic strategies to identify tissue-specific effects of cardiovascular drugsMinna T Jänis, Reijo Laaksonen, Matej Oresic
Swiss Medical Weekly|November 3, 2015
Use and role of monoclonal antibodies and other biologics in preventive cardiologyBaris Gencer, Reijo Laaksonen, Aliki Buhayer, et al.
Vascular Medicine (London, England)|February 1, 2006
DDAH gene and cardiovascular riskVeli-Pekka Valkonen, Tomi-Pekka Tuomainen, Reijo Laaksonen
Annals of Medicine|June 1, 2011
Clinical response to statins: mechanism(s) of variable activity and adverse effectsCesare R Sirtori, Giuliana Mombelli, Michela Triolo, et al.
European Heart Journal Open|August 3, 2022
Absolute and relative risk prediction in cardiovascular primary prevention with a modified SCORE chart incorporating ceramide-phospholipid risk score and diabetes mellitusMika Hilvo, Antti Jylhä, Mitja Lääperi, et al.
Plos One|March 31, 2015
Differential network analysis with multiply imputed lipidomic dataMaiju Kujala, Jaakko Nevalainen, Winfried März, et al.
Current Atherosclerosis Reports|April 29, 2010
Lipidomics: a tool for studies of atherosclerosisKim Ekroos, Minna Jänis, Kirill Tarasov, et al.
Pageof 16

Showing results (1-10 of 152) with videos related to

Sort By:
Pageof 16
Cardiovascular Drugs and Therapy|February 21, 2016
Identifying new Risk Markers and Potential Targets for Coronary Artery Disease: The Value of the Lipidome and MetabolomeReijo Laaksonen
Drug Discovery Today|September 24, 2013
Lipidomics in drug discoveryTerhi Vihervaara, Matti Suoniemi, Reijo Laaksonen
Angiology|July 18, 2008
Lipidomics-based safety biomarkers for lipid-lowering treatmentsReijo Laaksonen, Minna T Jänis, Matej Oresic
Expert Opinion on Drug Metabolism & Toxicology|July 10, 2008
Metabolomic strategies to identify tissue-specific effects of cardiovascular drugsMinna T Jänis, Reijo Laaksonen, Matej Oresic
Swiss Medical Weekly|November 3, 2015
Use and role of monoclonal antibodies and other biologics in preventive cardiologyBaris Gencer, Reijo Laaksonen, Aliki Buhayer, et al.
Vascular Medicine (London, England)|February 1, 2006
DDAH gene and cardiovascular riskVeli-Pekka Valkonen, Tomi-Pekka Tuomainen, Reijo Laaksonen
Annals of Medicine|June 1, 2011
Clinical response to statins: mechanism(s) of variable activity and adverse effectsCesare R Sirtori, Giuliana Mombelli, Michela Triolo, et al.
European Heart Journal Open|August 3, 2022
Absolute and relative risk prediction in cardiovascular primary prevention with a modified SCORE chart incorporating ceramide-phospholipid risk score and diabetes mellitusMika Hilvo, Antti Jylhä, Mitja Lääperi, et al.
Plos One|March 31, 2015
Differential network analysis with multiply imputed lipidomic dataMaiju Kujala, Jaakko Nevalainen, Winfried März, et al.
Current Atherosclerosis Reports|April 29, 2010
Lipidomics: a tool for studies of atherosclerosisKim Ekroos, Minna Jänis, Kirill Tarasov, et al.
Pageof 16